Based on this report and the preclinical data of ETP subtype susceptibility to BCL-2 inhibition, a phase I clinical trial testing the combination of venetoclax and mini-CVD in adults with Ph-neg B- and T- (including ETP) ALL was initiated at the Dana-Farber Cancer Institute and MD Anderson Cancer Center. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.